Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 6/20 | 0.62 |
| ▸ | GHSR | Q92847 | 5/20 | 0.62 |
| ▸ | NPY1R | P25929 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 3/20 | 0.59 |
| ▸ | NPY4R | P50391 | 3/20 | 0.59 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12912367 | 1.00 | KISS1R (0.62) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL31404052 | 0.95 | GHSR (0.68) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| Acetic Acid SCHEMBL29757019 | 0.92 | IL23R (0.59) | UTS2R | |
| Acetic Acid SCHEMBL29377757 | 0.92 | IL23R (0.59) | UTS2R | |
| SCHEMBL29550957 | 0.91 | KISS1R (0.64) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29550946 | 0.91 | KISS1R (0.64) | KISS1RGHSRNPY1RNPY2RNPY4R | |
| SCHEMBL30710492 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL7103421 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL14817785 | 0.91 | IL23R (0.59) | UTS2R | |
| SCHEMBL14509563 | 0.91 | GHSR (0.65) | KISS1RGHSRNPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-12110318-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4281180-A1 | SARS-COV-2 THERAPEUTICS | Model Medicines, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-4157448-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| WO-2022159763-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | KISS1R 1429/4885GHSR 2981/4885NPY1R 2626/4885 |
| US-12110318-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | KISS1R 327/4885GHSR 63/4885NPY1R 119/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | KISS1R 110/4885GHSR 1612/4885NPY1R 2068/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | KISS1R 503/4885GHSR 68/4885NPY1R 115/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | KISS1R 503/4885GHSR 68/4885NPY1R 115/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | KISS1R 470/4885GHSR 3829/4885NPY1R 2991/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | KISS1R 327/4885GHSR 63/4885NPY1R 119/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | KISS1R 240/4885GHSR 3355/4885NPY1R 2880/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | KISS1R 89/4885GHSR 710/4885NPY1R 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.